SeaStar Medical Q3 net loss $7.4M; FDA Approvable Letter for pediatric AKI device received

SeaStar Medical Holding Corp

2023-Q3 EPS reported -$1.02

Net loss $7.4M ($0.37/share) vs $1.9M ($0.26/share) YoY; no revenue as pre-commercial stage.
Cash $73,000 at Sep 30, raised $3.5M convertible notes in Aug-Sep 2023.
Received FDA Approvable Letter for SCD-PED; formal approval expected Dec 2023-Jan 2024.
Breakthrough Device Designation granted for cardiorenal and hepatorenal syndromes in Sep-Oct 2023.
NEUTRALIZE-AKI adult trial enrolled 7 patients; target 200 at up to 30 U.S. sites.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported financial results for three and nine months ended September 30, 2023.

Period: three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

reports financial results for the three and nine months ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-065623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.